Drugs / MK-4621
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03739138 | Dec 2018 → Mar 2021 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03065023 | Apr 2017 → May 2018 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03065023 ↗ |
| Action | Activate | “an oligonucleotide that binds and activates retinoic acid-inducible gene I (RIG-I)” PMID 35596791 ↗ May 2022 |
| Modality | Oligonucleotide (other) | “MK-4621, an oligonucleotide that binds and activates retinoic acid-inducible gene I (RIG-I)” PMID 35596791 ↗ May 2022 |
| Route | Other | “MK-4621 (0.2‒0.8 mg) was administered intratumorally” PMID 35596791 ↗ May 2022 |